

# Modification and Functional Design of Lipid-based Nanocarriers for Efficient Cancer Treatment

**Shiqi Huang, PhD, PostDoc Fellow**


College of Polymer Science and Engineering, Sichuan University, China

[huangshiqi@scu.edu.cn](mailto:huangshiqi@scu.edu.cn)

Wednesday, July 10, 2024



# | Liposomes developed for therapeutic applications




Concentric phospholipid bilayers

Spherical vesicles

## Steric Organization of Liposomes


Nontoxic & biodegradable



First proved  
by FDA in 1995

## Nanoparticles in Clinical Trials

from 2016 to 2021



## Liposomes on Market

(#: Europe, &: America, \*: Europe and America)

- Tumour, infection and vaccines....
- Intravenous, intramuscular and oral administration...

Int. J. Pharm. 2021, 601: 120571.




# Limitations

## Via tumour vasculature properties

- ◆ Unsatisfactory treatment outcomes

## Via receptor-specific ligands on liposome surfaces intended for cell binding

- ✓ Enhanced permeability
  - ✓ Reduced non-specific toxicity
  - ✓ Improved drug delivery efficiency
- **Carrier modification**



## “Magic Bullet”

- Precision facilitating diagnosis and therapy

*J. Cancer Res. Clin. Oncol. 2015, 141: 769-784.*

# Surface functionalization

## Biological barriers

- Abnormal TME
- Difficult penetration and diffusion



↓  
**CPPs**

- Lower toxicity
- Better accumulation

↓


c(RGDfK) peptide for highly expressed integrin receptors  $\alpha_v\beta_3$  binding  
+  
AGYLLGHINLHHLAHL(Aib)HHILCys peptide for low pH responsiveness  
+  
C18 stearyl chain for **membrane anchoring**

**TR CPPs**






# Characterization of functionalized liposomes TRAIL-[Lip-PTX]<sup>C18-TR</sup>




*J. Control. Release. 2020, 325, 10-24.*








# Therapeutic effect in B16F10 xenograft tumours



Fluorescence images of carriers



Quantification of PTX



Fluorescence images of tumour sections of TRAIL


- Enhanced accumulation in tumour sites

- Increased anti-tumour effect
- prolonged survival rates
- Upregulated death receptor levels

*J. Control. Release. 2020, 325, 10-24.*



# | Shape modification




## Spherical & Isotropic

- ✓ High cellular uptake
- ✓ Efficient retention
- ◆ Deficient penetration

## Non-spherical & Anisotropic

- ✓ Strong penetration
- ◆ Uniformly surface modification
- ◆ Deficient retention

How to combined advantages




Extracellular Matrix

- Blocking traditional ligands
- Relatively simple
- Highly expressed fibronectins
- Related to metastases


More stable targets

# Characterization of disk-shaped liposomes TRAIL-[ND-PTX]<sup>CR(NMe)EKA</sup>


A



B




C




TEM Images of (B) TRAIL-[ND-PTX]<sup>CR(NMe)EKA</sup> and (C) TRAIL-[Lip-PTX]<sup>CR(NMe)EKA</sup>

D




Zeta potential

E



*In vitro* fibrin clots binding

F




Fluorescence of tumour spheroids by CLSM

- Better penetration ability

Nano Res. 2022, 15: 728-737.



# Therapeutic effect in pulmonary metastasis melanoma model




- Enhanced pulmonary metastasis targeting ability
- Improved tumour penetration and retention than spherical liposomes



# Transcytosis-mediated infiltration of TRAIL-[ND-HCPT]<sup>GAC</sup>


GGT:  $\gamma$ -glutamyl Transpeptidase  
HCPT: Hydroxycamptothecin

A




- GGT triggered charge reversal of disk-shaped liposomes
- Enhanced tumour infiltration through transcytosis
- GGT is overexpressed in breast cancers and specifically catalyzes the hydrolysis to expose the hidden amino groups

B




GGT expression on tumour cell lines

C



Zeta potential variation curves

D




Intercellular transfer

Nano Res. 2024: 1-11.



# Therapeutic efficacy in orthotopic breast cancer models



Nano Res. 2024: 1-11.



# Size and rigidity modification

EMT: Epithelial Mesenchymal Transition


DOX: Doxorubicin

AA: Asiatic Acid




- Short blood circulation time
- Deficient treatment outcomes
- Lacking functionally decorated groups

Non-PEGylated and marketed in 2010



**Higher rigidity**

- ✓ Enhanced endocytosis
- ✓ Ameliorated anti-tumour efficacy
- ✓ Improved drug delivery efficiency



## Cholesterol Replacing Strategy

- Structural analogues with pharmacological activity
- Sensitized DOX resistant tumour cells
- Inhibited TGF- $\beta$  pathway, EMT process, and suppressed anti-tumour immune


**Smaller particle size**

- ✓ Prolonged circulation
- ✓ Enhanced penetration

*J. Control. Release. 2024, 366, 585–595.*




# Characterization of cholesterol replaced liposomes DOX-AALip



*J. Control. Release. 2024, 366, 585–595.*




# Therapeutic effect in orthotopic breast cancer and metastasis models



- Enhanced sensitivity to DOX
- Inhibited EMT process



# Immunogenetic assay



- Enhanced M1 type polarization of macrophages and recruitment of cytotoxic T cells

*J. Control. Release. 2024, 366, 585–595.*



## | Summary

- The design of lipid-based nanocarriers in **active targeting modification** could recognize specific tumour cells and display pH-triggered cell penetration activity in tumour microenvironment.
- The design in **shape and surface charge** could enhance the tumour retention and penetration capacity at the same time, as well as the infiltration ability through transcytosis.
- The design in **components** could harvest liposomes with higher rigidity and smaller particle size, hence prolonged blood circulation time and improved drug delivery efficiency.





# Thanks for Your Attention!



INTEGRATING  
**Delivery Science**  
ACROSS DISCIPLINES

